BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 33054455)

  • 1. Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits.
    Villani A; Cinelli E; Fabbrocini G; Lallas A; Scalvenzi M
    Expert Opin Drug Saf; 2020 Dec; 19(12):1585-1594. PubMed ID: 33054455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expert opinion on sonidegib efficacy, safety and tolerability.
    Villani A; Fabbrocini G; Costa C; Ocampo-Garza SS; Lallas A; Scalvenzi M
    Expert Opin Drug Saf; 2021 Aug; 20(8):877-882. PubMed ID: 33888008
    [No Abstract]   [Full Text] [Related]  

  • 3. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma.
    Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW
    J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
    Lacouture ME; Dréno B; Ascierto PA; Dummer R; Basset-Seguin N; Fife K; Ernst S; Licitra L; Neves RI; Peris K; Puig S; Sokolof J; Sekulic A; Hauschild A; Kunstfeld R
    Oncologist; 2016 Oct; 21(10):1218-1229. PubMed ID: 27511905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.
    Wahid M; Jawed A; Mandal RK; Dar SA; Khan S; Akhter N; Haque S
    Crit Rev Oncol Hematol; 2016 Feb; 98():235-41. PubMed ID: 26614022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma.
    Collier NJ; Ali FR; Lear JT
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1011-8. PubMed ID: 27636236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.
    Lyons TG; O'Kane GM; Kelly CM
    Expert Opin Drug Saf; 2014 Aug; 13(8):1125-32. PubMed ID: 25033383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
    Danhof R; Lewis K; Brown M
    Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis.
    Xie P; Lefrançois P
    J Am Acad Dermatol; 2018 Dec; 79(6):1089-1100.e17. PubMed ID: 30003981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature.
    Campione E; Di Prete M; Lozzi F; Lanna C; Spallone G; Mazzeo M; Cosio T; Rapanotti C; Dika E; Gaziano R; Orlandi A; Bianchi L
    Chemotherapy; 2020; 65(1-2):2-10. PubMed ID: 32777789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
    Leavitt E; Lask G; Martin S
    Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors.
    Kurnia Wijaya J; Djawad K; Wahab S; Nurdin A; Irawan Anwar A
    Actas Dermosifiliogr; 2022 May; 113(5):443-450. PubMed ID: 35697404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature.
    Passarelli A; Galdo G; Aieta M; Fabrizio T; Villonio A; Conca R
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
    Lyseng-Williamson KA; Keating GM
    Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Hedgehog pathway and its inhibitors: Emerging therapeutic approaches for basal cell carcinoma.
    Jain R; Dubey SK; Singhvi G
    Drug Discov Today; 2022 Apr; 27(4):1176-1183. PubMed ID: 34896624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.